Term
| Nicotinic Receptor Locations |
|
Definition
| NMJ, Autonomic ganglia, Adrenal medulla, CNS |
|
|
Term
|
Definition
|
|
Term
| Nicotinic Agonist Effects |
|
Definition
| relaxation of skeletal muscle, increased brain alertness, physical dependence via DA release |
|
|
Term
| Nicotinic Antagonist Effects (@NMJ) |
|
Definition
|
|
Term
| Beta-1 Receptor Locations |
|
Definition
| SA & AV node, cardiac myocytes, JG apparatus |
|
|
Term
|
Definition
|
|
Term
|
Definition
| increased chronotropy, increased inotropy, increased TPR&vasocon |
|
|
Term
| Beta-1 Antagonist Effects |
|
Definition
| decreased chronotropy, decreased dromotropy, decreased automaticity (which occurs after MI), decreased vasocon |
|
|
Term
| Beta-2 Receptor Locations |
|
Definition
| Smooth Muscle: bronchi, uterus, larger vessels, hepatocytes, skeletal muscle, eye |
|
|
Term
|
Definition
| Smooth muscle relaxation: bronchodilation, uterine relaxation, vasodilation, increased gluconeogenesis&glycogenolysis aka increased blood sugar, muscle tremors, increased aqueous humor production, reflex tachycardia |
|
|
Term
|
Definition
|
|
Term
| Beta-2 Antagonist Effects |
|
Definition
| Smooth muscle contraction: bronchoconstriction, uterine contraction, vasoconstriction, decreased gluconeogenesis, decreased aqueous humor production (&decreased palpitations in hypoglycemia aka warning sign to pt) |
|
|
Term
| Alpha-1 Receptor Locations |
|
Definition
| Smooth muscle: vascular, capillaries of nasal mucosa, bladder @ trigone sphincter, prostate gland, eye @ radial muscle |
|
|
Term
|
Definition
|
|
Term
|
Definition
| Vasoconstriction (for shock), reflex bradycardia, nasal mucosa constriction (for allergies), mydriatic eyedrop (for eye exams), light sensitivity, hypertension via increased TPR, decreased urine flow |
|
|
Term
| Alpha-1 Antagonist Effects |
|
Definition
| Vasodilation, First Dose Phenomenon, orthostatic hypotension, runny nose, increased urine flow in BPH, no reflex vasoconstriction (Alpha-1 is blocked), reflex tachycardia, miosis |
|
|
Term
| Alpha-1, Beta-1, Beta-2 Antagonist Effects |
|
Definition
| Vasodilation without reflex tachycardia (Beta-1 blocker) |
|
|
Term
| Alpha-2 Receptor Locations |
|
Definition
| CNS, post-ganglionic sympathetic nerve ending (auto receptor), eye |
|
|
Term
|
Definition
|
|
Term
|
Definition
| Decreased sympathetic outflow: vasodilation, decreased heart rate, sedation, decreased brain activity, decreased aqueous humor production, xerostomia |
|
|
Term
| Alpha-2 Antagonist Effects |
|
Definition
| Increased sympathetic outflow: increased heart rate, vasoconstriction, helps with ED :o |
|
|
Term
|
Definition
| Cardiac myocytes, renal artery vasculature |
|
|
Term
|
Definition
|
|
Term
|
Definition
| Increased inotropy, vasodilation of vascular artery (increased GFR), arrhythmia, angina |
|
|
Term
|
Definition
| Cardiac myocytes, AV&SA node, vascular smooth muscle of arteries and arterioles ONLY |
|
|
Term
| L-Type VGCC Receptor Type |
|
Definition
| Voltage Gated Calcium Channel DUH~ |
|
|
Term
| L-Type VGCC Agonist Effects |
|
Definition
| Increased inotropy, increased chronotropy, increased dromotropy, vasoconstriction |
|
|
Term
| L-Type VGCC Antagonist Effects |
|
Definition
| Vasodilation (DHP CCBs), decreased inotropy (nonDHP CCBs), decreased chronotropy (nonDHP CCBs), decreased automaticity (nonDHP CCBs) |
|
|
Term
| HMG CoA Reductase Inhibitor Effects |
|
Definition
| Decrease LDL by inhibiting de novo synthesis |
|
|
Term
| HMG CoA Reductase Inhibitor Pleitropic Effects |
|
Definition
| Decreased endothelial cell disfunction, increased plaque stability, decreased platelet activation, decreased vascular inflammation |
|
|
Term
| Bile Acid Sequestrant Effects |
|
Definition
| Decreased LDL via excretion of cholesterol, Increased triglycerides due to increased VLDL synthesis due to body having to make more cholesterol |
|
|
Term
|
Definition
| Decreased triglycerides via increased breakdown and decreased synthesis |
|
|
Term
|
Definition
| Increased HDL via decreased degredation of its Apoprotein, decreased triglycerides via decreased synthesis and decreased lipolysis |
|
|
Term
|
Definition
| Decreased LDL via inhibited cholesterol absorption in smint |
|
|
